Home > PJ (current issue) > Letters | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7266 p322
13 September 2003

This page
Reprint
Photocopy

   

PDF* 85K

Letters

  New Contract
  CPD
  Registartion exam
  IBS
  Storage temperature
  The Society


Letters to the Editor

IBS

More caution required in use of antispasmodics?

From Dr M. Griffiths, MRPharmS

The proposed reclassification of hyoscine butylbromide as a general sale list medicine for irritable bowel syndrome (PJ, 23 August, p228) adds to the confusion which already exists over the use of smooth muscle relaxants for diverticular disease of the colon.

When infection (diverticulitis) is absent, patients are often told that their symptoms of colon malfunction are due to irritable bowel syndrome, which is inaccurate because IBS by definition excludes any physical colon changes. Some consultants think that diverticula are irrelevant when IBS is diagnosed.1 This opinion, that diverticular disease does not cause functional problems, is at odds with the many researchers who have used these same “IBS” symptoms to evaluate and promote treatments for diverticular disease, including a high fibre diet.

As well as the structural changes, raised intracolonic pressure and altered gut flora, differences in neurotransmitters, receptors and enzyme levels have been reported with diverticular disease. Differences in response to acetylcholine have also been reported. There are no randomised controlled trials supporting a role for antispasmodics in diverticular disease2 and they have not shown any consistent beneficial effects.3 Nevertheless, they are prescribed and purchased as “intestinal analgesics” and painful diverticular disease is an indication for one product.

Pain in diverticular disease can arise from diarrhoea, constipation, distension by gas, strictures, partial obstruction, adhesions, inflammation, infection and the complications which lead to surgery. Because many sufferers are elderly, faecal impaction, colon atony, and side effects from treatments for other conditions could also be involved. When medical opinion is so confused about the relationship between lBS and diverticular disease, should there be more caution in the use of antispasmodics?

Mary Griffiths
Macclesfield, Cheshire

References
1. Heaton KW, Thompson WG. Fast facts — irritable bowel syndrome. Oxford: Health Press Ltd; 1999.
2. Afzal NA, Thomson M. Diverticular disease in adolescence. Best Pract Res Clin Gastroenterol 2002; 16:621–34.
3. Murray CDR, Emmanuel AV. Medical management of diverticular disease. Best Pract Res Clin Gastroenterol 2002;16:611–20.

Send your letter to The Editor

Previous Topic (Registration exam)
Next Topic (Storage temperatures)

  * PDF files on PJ Online require Acrobat Reader 4 or later.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal